Cover Image

Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

Two phase 3 trials compared 28-35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty.

Saved in:
Bibliographic Details
Main Authors: Eriksson, Bengt (Author) , Dahl, Ola E. (Author) , Rosencher, Nadia (Author) , Clemens, Andreas (Author) , Hantel, Stefan (Author) , Feuring, Martin (Author) , Kreuzer, Jörg (Author) , Huo, Michael (Author) , Friedman, Richard J. (Author)
Format: Article (Journal)
Language:English
Published: 17 November 2015
In: Thrombosis journal
Year: 2015, Volume: 13
ISSN:1477-9560
DOI:10.1186/s12959-015-0067-8
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12959-015-0067-8
Get full text
Author Notes:Bengt I. Eriksson, Ola E. Dahl, Nadia Rosencher, Andreas Clemens, Stefan Hantel, Martin Feuring, Jörg Kreuzer, Michael Huo and Richard J. Friedman
Description
Summary:Two phase 3 trials compared 28-35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty.
Item Description:Gesehen am 16.07.2020
Physical Description:Online Resource
ISSN:1477-9560
DOI:10.1186/s12959-015-0067-8

Similar Items